Novavax Prices Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- S&P 500 set to open near record highs as Treasury yields cool, oil slips
- Oil slips as Mideast exports, G7 stockpile ease supply concerns
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
- HubSpot to cut 7% of workforce in restructuring plan
- Paramount Skydance to close WBD deal, change ticker to SKYD
- Citi cuts investment banking analyst program to two years - Bloomberg
- Nasdaq notches record high close as investors focus on earnings
- Francis Halzen wins Nobel Physics Prize for Antarctic 'ghost particle' hunt
Novavax, Inc. (NVAX) 25M Offering Prices at $4/sh
June 6, 2014 7:16 AM EDTNovavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that it has priced an underwritten public offering of 25 million shares of common stock at a price to the public... More



